Evaluation of 89Zirconium-labelled Girentuximab PET-CT Imaging in Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Gastroenteropancreatic Neuroendocrine Neoplasms

The primary objective of this study is to assess the **imaging performance** of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in patients diagnosed with **HepatoCellular Carcinoma**, **IntraHepatic CholangioCarcinoma**, or **Gastro-Entero-Pancreatic Neuroendocrine Neoplasms**. This evaluation is clinically relevant as it may enhance diagnostic accuracy and improve the management of these malignancies by providing detailed imaging insights.

The clinical trial involves participants diagnosed with **Gastro-Entero-Pancreatic Neuroendocrine Neoplasms**, **HepatoCellular Carcinoma**, and **IntraHepatic CholangioCarcinoma**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial population selection includes a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Participants' general health status, lifestyle considerations such as diet, physical activity, or habits, and specific inclusion or exclusion criteria are not detailed in the available data.

The clinical trial is designed to evaluate the imaging performance of **89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT** in patients diagnosed with **Hepatocellular Carcinoma**, **Intrahepatic Cholangiocarcinoma**, or **Gastro-Entero-Pancreatic Neuroendocrine Neoplasms**. This study is structured as a prospective pilot trial and is anticipated to commence recruitment on December 1, 2024, with an estimated completion date of September 1, 2027. The trial will employ a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be involved in the study for its entire duration unless specific conditions necessitate early termination, such as adverse events or withdrawal of consent.

The sequence of study visits will begin with an inclusion visit, where participants will undergo screening to confirm eligibility based on predefined criteria. Following successful inclusion, participants will attend scheduled follow-up visits, which will be conducted at regular intervals to monitor the imaging outcomes and any potential side effects. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the imaging performance of the investigational product. The expected length of participant involvement will span the entire trial duration, with early termination considered only under specific circumstances, such as significant protocol deviations or safety concerns. The trial's methodology and design are meticulously crafted to ensure the collection of robust and scientifically valid data, contributing to the understanding of the investigational product's efficacy in the specified medical conditions.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for both experimental and non-experimental treatments is not available in the provided data.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is scheduled to commence recruitment on December 1, 2024, with an estimated completion date of September 1, 2027. The trial is categorized under phase 9, indicating an advanced stage of clinical research. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely employ standard methodologies for measuring and analyzing efficacy outcomes. These may include validated scales, laboratory tests, or patient-reported outcomes, assessed at predetermined timepoints throughout the trial duration. The trial's design will ensure that data collection and analysis adhere to rigorous scientific standards to accurately determine the efficacy of the intervention under investigation.